Paris

• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 7 2023-12-01 participants with isolated methylmalonic acidemia (MMA) due to methylm
• Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l … Recruiting
  2023-504555-27-00 5 2023-11-28 Myelodysplastic syndrome (MDS)
• Study aiming to assess the clinical impact of dostarlimab on occurrence of second primary cancer in patients with cured primary cancer Recruiting
  2022-501316-34-00 4 2023-11-27 Patient cured from a primary cancer and at risk of 2nd cancer
• Impact of rifampicin in treatment outcome of Cutibacterium spp. prosthetic joint infections - RIFACute Recruiting
  2022-502974-18-00 10 2023-11-27 C. spp. prosthetic joint infection
• ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting
  2023-503533-21-00 4 2023-11-21 Low-grade serous ovarian cancer
• A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory … Recruiting
  2023-503206-37-00 5 2023-11-20 Mantle Cell Lymphoma (MCL)
• International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting
  2022-501869-41-00 9 2023-11-14 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment … Recruiting
  2023-505420-62-00 5 2023-11-09 Multiple sclerosis
• INduction in Sensitized kidney Transplant recipients without pre-Existing donor-specific AntiboDies: a randomized multicentre trial between … Recruiting
  2022-502007-30-00 5 2023-11-07 Kidney transplant
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO Recruiting
  2022-501057-36-00 5 2023-10-24 ANCA-associated vasculitis
• A Phase 1/2 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B Cell and T-Cell Lymphomas Recruiting
  2022-502299-21-00 1 2023-10-18 Relapsed/refractory (R/R) B-cell and T-cell lymphomas
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 5 2023-10-17 Thromboprophylaxis in good and intermediate prognosis advanced germ ce
• Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Recruiting
  2024-518844-20-00 10 2023-10-03 Treatment of Acute Gout Flare
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting
  2022-502281-25-00 5 2023-09-27 Focal Onset Seizures
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 B-Cell Malignancies
• FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul … Recruiting
  2022-502019-12-00 5 2023-09-14 acute myeloid leukemia
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Year of Age and Older Recruiting
  2022-503081-74-00 5 2023-09-05 Cystic Fibrosis
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma

Showing 1,033–1,056 of 2,286 trials